1. Home
  2. STTK vs CHMG Comparison

STTK vs CHMG Comparison

Compare STTK & CHMG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Shattuck Labs Inc.

STTK

Shattuck Labs Inc.

HOLD

Current Price

$5.99

Market Cap

275.9M

Sector

Health Care

ML Signal

HOLD

Logo Chemung Financial Corp

CHMG

Chemung Financial Corp

N/A

Current Price

$53.60

Market Cap

257.8M

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
STTK
CHMG
Founded
2016
1833
Country
United States
United States
Employees
N/A
343
Industry
Biotechnology: Pharmaceutical Preparations
Major Banks
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
275.9M
257.8M
IPO Year
2020
1995

Fundamental Metrics

Financial Performance
Metric
STTK
CHMG
Price
$5.99
$53.60
Analyst Decision
Buy
Hold
Analyst Count
7
2
Target Price
$7.00
$57.00
AVG Volume (30 Days)
574.2K
3.6K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
2.57%
EPS Growth
53.02
N/A
EPS
N/A
1.53
Revenue
$1,000,000.00
N/A
Revenue This Year
N/A
$37.32
Revenue Next Year
N/A
$9.13
P/E Ratio
N/A
$35.27
Revenue Growth
N/A
N/A
52 Week Low
$0.69
$40.71
52 Week High
$6.13
$65.50

Technical Indicators

Market Signals
Indicator
STTK
CHMG
Relative Strength Index (RSI) 72.78 34.49
Support Level $1.85 $52.75
Resistance Level N/A $53.51
Average True Range (ATR) 0.40 1.40
MACD 0.17 -0.44
Stochastic Oscillator 89.34 5.38

Price Performance

Historical Comparison
STTK
CHMG

About STTK Shattuck Labs Inc.

Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.

About CHMG Chemung Financial Corp

Chemung Financial Corp is a bank holding firm. Through its subsidiaries, the company provides various financial services, including demand, savings, and time deposits, commercial, residential, and consumer loans, letters of credit, wealth management services, employee benefit plans, insurance products, mutual funds, and brokerage services, among others. The company's reportable segments are Core Banking, Wealth Management (WMG) services, and Holding company and CFS. Maximum revenue is generated from the Core Banking segment, which derives revenue by attracting deposits from the general public and using such funds to originate different types of loans, and to invest in securities. The Wealth Management (WMG) services segment provides trust and investment advisory services to clients.

Share on Social Networks: